The AKTA oligosynt oligonucleotide synthesizer is a compact, fully automated oligonucleotide synthesizer built for research and process development laboratories. The system supports a robust and easily scalable oligonucleotide synthesis process and transfer to larger oligonucleotide synthesizers with high yield and quality.
As your dedicated partner in therapeutic development, Mission Bio provides robust single-cell analysis so you can characterize your cell and gene therapies better.
Cytokine assays in the Opto Cell Therapy Development workflow allow simultaneous functional interrogation of thousands of individual T cells as they interact with antigen-presenting cells, granting insight into the heterogenous mechanisms that regulate cytokine secretion. The automated assays also allow live recovery of individual clones for downstream analysis. Cytokine assays and cell surface markers can be customized.
Defined, serum-free, xeno-free reagents are essential tools for all human mesenchymal stem cell (hMSC) research having potential clinical applications. The NutriStem MSC Culture System includes defined reagents ideal for translational research use. hMSCs cultured in serum-free, xeno-free NutriStem MSC XF Medium show superior proliferation and self-renewal potential in comparison to serum-containing media and other serum-free media.
Streamline your process with a clonal imager that sets the standard for high-contrast imaging. Reduce time and effort with artificial intelligence driven Automated Evidence of Clonality.
Exosomes can be purified from cultured cells, serum, bacteria, and other biological fluids. Explore large volume and small-scale exosome purification, filter products for the process, and applications of the products.
The BioAccord LC-MS System with dedicated workflows for the Sartorius Ambr 15 and small bioreactors enables process engineers to directly measure Product Quality Attributes (PQAs) and cell culture media.
Learn about three different grades of high-quality synthetic sgRNAs that will help support every step of your CRISPR-based therapy development process.
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr Spark instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
Ensure our newsletter reaches your inbox by following these whitelist instructions. This
newsletter is being sent to {{lead.Email Address}}. If you need to update your
preferences, please visit your user profile. To cancel your subscription to the newsletter, please opt out.
This website uses cookies to ensure you get the best experience on our website. Learn more